HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) major shareholder Holdings A/S Novo sold 47,162 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $2.02, for a total transaction of $95,267.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Thursday, August 24th, Holdings A/S Novo sold 382,437 shares of HTG Molecular Diagnostics stock. The stock was sold at an average price of $1.91, for a total transaction of $730,454.67.
- On Friday, August 25th, Holdings A/S Novo sold 1,149,813 shares of HTG Molecular Diagnostics stock. The stock was sold at an average price of $1.81, for a total transaction of $2,081,161.53.
- On Tuesday, August 22nd, Holdings A/S Novo sold 80,586 shares of HTG Molecular Diagnostics stock. The stock was sold at an average price of $2.07, for a total transaction of $166,813.02.
HTG Molecular Diagnostics, Inc. (NASDAQ HTGM) traded down 4.52% during midday trading on Friday, hitting $1.90. 1,173,177 shares of the stock were exchanged. The company has a 50 day moving average price of $2.27 and a 200 day moving average price of $3.38. The firm’s market capitalization is $21.75 million. HTG Molecular Diagnostics, Inc. has a one year low of $1.20 and a one year high of $13.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.60). HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.80 million. Equities analysts anticipate that HTG Molecular Diagnostics, Inc. will post ($2.29) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “HTG Molecular Diagnostics, Inc. (HTGM) Major Shareholder Holdings A/S Novo Sells 47,162 Shares” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/08/26/htg-molecular-diagnostics-inc-htgm-major-shareholder-holdings-as-novo-sells-47162-shares.html.
Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock valued at $359,000 after buying an additional 37,841 shares during the period. Granahan Investment Management Inc. MA acquired a new position in shares of HTG Molecular Diagnostics during the first quarter valued at about $228,000. Two Sigma Securities LLC acquired a new position in shares of HTG Molecular Diagnostics during the first quarter valued at about $150,000. UBS Group AG acquired a new position in shares of HTG Molecular Diagnostics during the first quarter valued at about $137,000. Finally, Renaissance Technologies LLC raised its position in shares of HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock valued at $130,000 after buying an additional 14,206 shares during the period. 26.26% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently commented on the stock. Rodman & Renshaw boosted their target price on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, May 16th. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Thursday, May 11th. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of HTG Molecular Diagnostics in a report on Thursday, June 29th. Finally, ValuEngine upgraded shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a report on Monday, July 17th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $5.75.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
